Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

Sunitinib in Certain Subtypes of Soft Tissue Sarcomas

Phase 2

Terminated

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Sunitinib

First Posted Date: 2009-03-11

Last Posted Date: 2019-11-04

Lead Sponsor: Columbia University

Target Recruit Count: 10

Registration Number: NCT00859456

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Vitamin D in Postmenopausal Women at High Risk for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cholecalciferol
Drug: Placebo capsule

First Posted Date: 2009-03-11

Last Posted Date: 2017-09-27

Lead Sponsor: Columbia University

Target Recruit Count: 20

Registration Number: NCT00859651

Locations: 🇺🇸
Columbia University, New York, New York, United States

Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Emphysema
Endothelial Dysfunction

First Posted Date: 2009-02-13

Last Posted Date: 2012-01-16

Lead Sponsor: Columbia University

Target Recruit Count: 4359

Registration Number: NCT00843271

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

Not Applicable

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Other: Placebo
Dietary Supplement: n-3 polyunsaturated fatty acids

First Posted Date: 2009-02-03

Last Posted Date: 2020-11-17

Lead Sponsor: Columbia University

Target Recruit Count: 40

Registration Number: NCT00835289

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Obesity, Oral Contraception, and Ovarian Suppression

Phase 4

Completed

Conditions: Ovarian Suppression

Interventions: Drug: Low dose formulation
Drug: High dose formulation

First Posted Date: 2009-01-23

Last Posted Date: 2019-04-30

Lead Sponsor: Columbia University

Target Recruit Count: 226

Registration Number: NCT00827632

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Acupuncture for Aromatase Inhibitor Induced Joint Pain

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Sham Acupuncture
Procedure: Acupuncture

First Posted Date: 2009-01-22

Last Posted Date: 2017-11-06

Lead Sponsor: Columbia University

Target Recruit Count: 40

Registration Number: NCT00826397

Locations: 🇺🇸
Columbia University, New York, New York, United States

Post-treatment Care of Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Neoplasm

Interventions: Behavioral: Survivorship Intervention
Behavioral: Facing Forward

First Posted Date: 2009-01-13

Last Posted Date: 2017-06-19

Lead Sponsor: Columbia University

Target Recruit Count: 140

Registration Number: NCT00821288

Locations: 🇺🇸
Columbia Unviersity Medical Center, New York, New York, United States

Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Physical activity and dietary change

First Posted Date: 2008-12-19

Last Posted Date: 2013-02-22

Lead Sponsor: Columbia University

Target Recruit Count: 42

Registration Number: NCT00811824

Locations: 🇺🇸
Columbia University, New York, New York, United States

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Phase 1

Terminated

Conditions: Neuroblastoma
Immunodeficiencies
Anemia
Leukemia
Lymphoma

Interventions: Radiation: Total Body Irradiation
Drug: Alemtuzumab
Drug: Busulfan
Drug: Melphalan
Drug: Fludarabine
Drug: Phenytoin
Drug: Rabbit Antithymocyte Globulin
Drug: Cyclophosphamide
Drug: Horse Antithymocyte Globulin
Drug: Thiotepa

First Posted Date: 2008-12-04

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 1

Registration Number: NCT00801931

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

Denileukine Diftitox for Relapsed ALCL

Phase 2

Withdrawn

Conditions: Anaplastic Large-Cell Lymphoma

Interventions: Drug: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
Drug: Denileukin Diftitox

First Posted Date: 2008-12-04

Last Posted Date: 2013-05-15

Lead Sponsor: Columbia University

Registration Number: NCT00801918

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy